Principal Financial Group
CTMX icon

Principal Financial Group’s CytomX Therapeutics CTMX Stock Holding History

Principal Financial Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,811
Closed -$29K – 2533
2022
Q1 		$29K Buy
10,811
+712
+7% +$2.73K ﹤0.01% 2511
2021
Q4 		$44K Sell
10,099
-15,502
-61% -$90.8K ﹤0.01% 2488
2021
Q3 		$131K Buy
25,601
+10,645
+71% +$57K ﹤0.01% 2476
2021
Q2 		$95K Sell
14,956
-8,443
-36% -$65.7K ﹤0.01% 2539
2021
Q1 		$181K Buy
23,399
+11,336
+94% +$89.7K ﹤0.01% 2390
2020
Q4 		$79K Buy
+12,063
New +$86.2K ﹤0.01% 2373
2018
Q4 		– Sell
-18,480
Closed -$342K – 2256
2018
Q3 		$342K Buy
18,480
+470
+3% +$10.7K ﹤0.01% 2048
2018
Q2 		$412K Buy
+18,010
New +$460K ﹤0.01% 2003

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Principal Financial Group's CTMX Position: Q2 2022 in Review

Principal Financial Group sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 10,811 shares — an estimated $29K sold.

Principal Financial Group first reported a position in CTMX in Q2 2018 and held it in 8 quarters. The position peaked at $412K in Q2 2018. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Principal Financial Group reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Principal Financial Group sold 10,811 CytomX Therapeutics shares in Q2 2022, an estimated $29K.
  • Principal Financial Group first reported a position in CytomX Therapeutics in Q2 2018 and held it in 8 quarters.
  • Principal Financial Group's CytomX Therapeutics position peaked at $412K in Q2 2018.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Principal Financial Group's 13F filing for Q2 2022, filed 10 Aug 2022.